If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
The digital elevation model (DEM) is a raster-based digital dataset of the topography (hypsometry and/or bathymetry) of all or part of the Earth (or a telluric planet). The pixels of the dataset are each assigned an elevation value, and a header portion of the dataset defines the area of coverage, the units each pixel covers, and the units of elevation (and the zero-point). DEMs may be derived from existing paper maps and survey data, or they may be generated from new satellite or other remotely sensed radar or sonar data.
== Structure == Glutamine can exist in either of two enantiomeric forms, L-glutamine and D-glutamine. The L-form is found in nature. Glutamine contains an α-amino group which is in the protonated −NH3+ form under biological conditions and a carboxylic acid group which is in the deprotonated −COO− form, known as carboxylate, under physiological conditions.
== Structure == Factor XIII of human blood is a heterotetramer of two A and two B linear polypeptides or "units". A units are potentially catalytic; B units are not. A units form a dimeric center. Non-covalently bound B units form a ring-like structure around the center. B units are removed when XIII is activated to XIIIa. Dimers containing only A units also occur within cells such as platelets. Large quantities of singular B units (monomers) also occur within blood. These dimers and monomers are not known to participate in coagulation, whereas the tetramers do. A units have a mass of about 83 kDa, 731 amino acid residues, 5 protein domains (listed from the N-terminal to C-terminal, residue numbers are in brackets):
Sources: en.wikipedia.org
== Awards == 2023 Tung-Ho Outstanding Research Award, THS Foundation 2023 16th Taiwan Outstanding Women in Science Awards, Wu Chien Shiung Education Foundation & L'ORÉAL Taiwan 2022 Outstanding Research Award, National Science and Technology Council 2022 Outstanding Research Award, National Science and Technology Council 2021 National Innovation Award 2020 Taiwan Society for Mass Spectrometry Medal 2011 Taiwan Society for Mass Spectrometry Outstanding Scholar Award 2007 Federation of Asian Chemical Societies Distinguished Young Chemists Award 2006 Chinese Chemical Society Outstanding Young Investigator Award
The Half-Life franchise has received critical praise for its in-depth fictional universe, including numerous characters who would go on to become well known in the gaming sphere. The original Half-Life introduces Gordon Freeman, a theoretical physicist working at the Black Mesa Research Facility who serves as the main silent playable protagonist for the franchise. Freeman is hired and put into stasis by the G-Man, an enigmatic and questionable businessman with capabilities and powers beyond any ordinary human being. The expansion packs to the original game introduce other protagonists and characters, such as Corporal Adrian Shephard in Half-Life: Opposing Force and Black Mesa security guard Barney Calhoun in Half-Life: Blue Shift (who reappears in the Half-Life 2 games). Half-Life 2 and the games following it introduce a new, more focused cast of characters fighting the oppressive Combine Empire. This includes Alyx Vance, a prominent member of the Resistance and the daughter of former Black Mesa scientist Eli Vance. Alyx is the protagonist of Half-Life: Alyx. The games have depicted numerous alien races and creatures, many from the Xen border world. Some of the most notable include the Vortigaunts, a highly intelligent alien race that often assists Freeman after he saves them from oppression, and headcrabs, parasitic aliens who latch on to heads and convert humans into mindless zombies, sometimes used as biological weapons.
Also in 1934, scientists Ernest Rutherford, Mark Oliphant, and Paul Harteck, produced the radioisotope tritium (hydrogen-3, 3H) by hitting deuterium with high-energy nuclei. The deuterium used in the experiment was a generous gift of heavy water from UC Berkeley physicist Gilbert N. Lewis. Bombarding deuterium produced two previously undetected isotopes, helium-3 (3He) and 3H. Rutherford and his colleagues successfully created 3H, but incorrectly assumed that 3He was the radioactive component. The work of Luis Walter Alvarez and Robert Cornog first isolated 3H and reversed Rutherford's incorrect notion. Alvarez reasoned that tritium was radioactive, but did not measure the half-life, though calculations at the time suggested >10 years. At the end of World War II, physical chemist Willard Libby detected the residual radioactivity of a tritium sample with a Geiger counter, providing a more accurate understanding of the half-life, now accepted as 12.3 years.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.